donate now The Fatty Liver Foundation


International NASH Day programs include two live, interactive webinars on NAFLD/NASH screening and a development update on FLF’s WELLNESS LEAGUE, the first community-driven health and wellness platform for people at-risk of or living with NAFLD/NASH in the United States


June 9, 2022; Boise, IDAHO On the occasion of International NASH Day 2022, Fatty Liver Foundation (FLF) brings three interactive programs to the public that offer information, inspiration, and support for populations affected by non-alcoholic fatty liver disease (NAFLD) and its more advanced form, non-alcoholic steatohepatitis (NASH). FLF, along with its collaborators Sano Genetics and Hepatitis B Initiative of Washington, DC (HBI-DC), as well as other key stakeholders are also highlighting the need for urgent action to increase early stage NAFLD detection, screening, and diagnosis to significantly improve patients’ chances of survival. 

Read more

Fatty Liver Disease: Fight against ‘Silent Epidemic’ boosted by genetic testing and lifestyle support for at-risk Americans

New collaboration offers free DNA Testing for Americans at risk of, and living with, NAFLD/NASH

Read more

Fatty Liver Foundation Launches the State of NAFLD/NASH Care in America ™ Initiative to Support Improved Patient Care Experience

April 18, 2022; Boise, IDAHO The Fatty Liver Foundation (FLF) today announced the launch of The State of NAFLD/NASH Care in America™, a first-of-its-kind national initiative that aims to make a big impact within the NAFLD/NASH community by surveying the lived experiences of adults with NAFLD/NASH in the United States and fostering the continuous development and integration of actionable solutions to improve the diagnosis, treatment, care, and support for people with NAFLD/NASH.

Read more

Fatty Liver Foundation Announces the Publication of Data from the Screening for Undiagnosed NAFLD/NASH Study (SUNN-1) in PLOS ONE

The study highlights critical need to take urgent actions for proactive and routine screening of NAFLD/NASH among at-risk asymptomatic adults in the United States


November 30, 2021; Boise, IDAHO The Fatty Liver Foundation (FLF) today announced data from its SUNN-1 study published in PLOS ONE, a peer-reviewed, open access scientific journal, evaluating risk factors for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) based on vibration controlled transient elastography (VCTE) and controlled attenuation parameter (CAP) among a self-selecting group of undiagnosed and asymptomatic individuals in real-life, community-based settings. 

Read more

Fatty Liver Foundation to Amplify the Voices of People with NAFLD/NASH and Highlight New NAFLD/NASH Screening Initiatives While Attending The Liver Meeting® 2021


Thursday, November 11, 2021, Boise, IDAHO The Fatty Liver Foundation (FLF) today announced its activities while attending the 72nd American Association for the Study of Liver Diseases (AASLD) Annual Meeting, taking place from November 12 to 15, 2021. 

Read more

Fatty Liver Foundation Launches a Public-Private Partnership to Combat the Silent Epidemic of Nonalcoholic Fatty Liver Disease (NAFLD)

Building on the experience of FLF, the leading patient advocacy organization, the NAFLD Screening Fund aims to identify and support at-risk populations to combat the rising incidence and mortality of NAFLD in the United States.


Monday, October 4, 2021, Boise, IDAHO As October marks National Liver Awareness Month, the Fatty Liver Foundation (FLF) is launching the NAFLD Screening Fund, a new five-year, multi-stakeholder, public-private partnership aimed at accelerating progress in the detection, diagnosis, staging, care, and research of NAFLD among at-risk and asymptomatic populations in the United States, where there is a significant unmet need.

Read more

The Fatty Liver Foundation and Fibronsotics form a patient education partnership

FLF Launches a Patient Education Partnership to Expand Patient Outreach and Accelerate Early Identification of People with Undiagnosed Nonalcoholic Steatohepatitis  

BOISE, ID; Dec 07, 2020 The Fatty Liver Foundation (FLF) announced today it is launching a new patient education partnership, in collaboration with Fibronostics, to meet the urgent need for early screening, identification, and intervention for people at-risk of developing nonalcoholic steatohepatitis. FLF and Fibronostics will work toward a shared mission of facilitating access to non-invasive tests that can help identify those at-risk of developing NASH as early as possible.

Non-alcoholic fatty liver disease (NAFLD) is an umbrella term that describes a spectrum of conditions ranging from non-alcoholic fatty liver to the more aggressive nonalcoholic steatohepatitis (NASH). NASH is a serious condition and can cause scarring of the liver, which leads to cirrhosis, as well as metabolic complications making it a unique medical condition requiring complex care. Comorbidities, such as metabolic syndrome, obesity and NASH, increase the risk factor and severity for patients with the COVID-19 virus.

Since NASH is asymptomatic until advanced disease, many patients are only identified at advanced stages. One of FLF’s core priorities is to educate people at-risk for NASH and facilitate access to early screening, diagnosis, and care that can save lives.

Read more

Gabriella Wan joins the Fatty Liver Foundation

BOISE, IDAHO (October 13, 2020) — Fatty Liver Foundation today announced the appointment of Gabriella A. Wan as Executive Assistant and Program Coordinator effective October 9, 2020. Gabriella will provide administrative support of the CEO’s office and program coordination of the executive leadership team.


Gabriella joins the Fatty Liver Foundation from Georgetown University Department of Global Health where she served as Research Assistant with a focus on health economics and financing. She previously served as Administrative Assistant at Georgetown University Graduate School of Arts and Sciences where she provided administrative support to the Deans’ Offices.

Gabriella received a Bachelor of Science in Global Health and a Master of Science in Global Health from Georgetown University. She also participated in the School for International Training (SIT) Honors Program where she engaged in field-based global health programs in Washington, DC, Vietnam, South Africa, and Argentina.

“We are thrilled to welcome Gabriella to the team,” said Wayne Eskridge, Co-Founder and CEO of Fatty Liver Foundation. “Her new role is essential for supporting the growth of our operations and programs as well as advancing our mission to identify and educate people who are at-risk for NAFLD/NASH or living with NASH.”

#  #  #


Fatty Liver Foundation Appoints New Chief Financial Officer

BOISE, IDAHO (April 30, 2020) Fatty Liver Foundation today announced the appointment of Matthew J. Yust as Chief Financial Officer effective May 1, 2020. Yust will join the organization’s executive leadership team.

Yust joins Fatty Liver Foundation from PILnet, the global network for public interest law, where he served as Chief Financial Officer and oversaw the financial management operations for an $8 million annual budget. He previously served in other senior executive roles at non-profit organizations, including as Director of Finance and Operations at Global Business Coalition on HIV/AIDS, Tuberculosis and Malaria; Director of Finance and Operations at Clinton Foundation; Vice President and Chief Financial Officer at James Beard Foundation; and Chief Financial Officer at Family Care International.

“We are thrilled to welcome Matt to the team,” said Wayne Eskridge, Co-Founder and CEO of Fatty Liver Foundation. “His expertise will enable us to continue our focus on fiscal responsibility that is vital to support the growth of our operations and to best serve our mission to identify asymptomatic, undiagnosed Americans with fatty liver disease, and to educate them on the lifestyle changes needed to halt or minimize disease progression.”



Read more

Echosens Aligns with Fatty Liver Foundation to Accelerate Screening for Undiagnosed Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

WALTHAM, Mass.--(BUSINESS WIRE)--Echosens, a high-technology company offering the FibroScan family of products, is proud to support the Fatty Liver Foundation (FLF), a non-profit organization dedicated to fighting fatty liver disease and advocating for ongoing screening of undiagnosed nonalcoholic fatty liver disease (NAFLD) and its more severe form nonalcoholic steatohepatitis (NASH). FLF is raising awareness about this asymptomatic condition affecting as many as one-in-three Americans. As part of its initiatives, FLF is using FibroScan, a painless, five-minute test at the point of care to help physicians detect, monitor and prevent the progression of liver disease among patients who are often asymptomatic and may be high-risk.

Read more